# An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604

> **NCT06157255** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 8 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** AZD4604 Inhalation Powder, 1 mg
- **DRUG:** [14C]AZD4604 Solution for Infusion 6 μg/mL (NMT 37.0 kBq/5 mL)
- **DRUG:** [14C]AZD4604 Oral Solution, 4 mg (NMT 37.0 kBq)

## Key facts

- **NCT ID:** NCT06157255
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-16
- **Primary completion:** 2024-05-20
- **Final completion:** 2024-05-20
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2024-05-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06157255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06157255, "An ADME Study of [14C]AZD4604 and the Absolute Bioavailability of AZD4604". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06157255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*